Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women.
Inhaled corticosteroids are widely used in the treatment of bronchial asthma, but it is still uncertain whether long-term use of the inhaled corticosteroids affects bone metabolism in asthmatic patients. In this study, we examined the effect of inhaled beclomethasone dipropionate (BDP) on bone mineral density (BMD) and biochemical markers of bone metabolism in pre- and early postmenopausal asthmatic women. Thirty-six (17 premenopausal and 19 early postmenopausal) asthmatic women and 45 healthy control (24 premenopausal and 21 early postmenopausal) women were investigated. All the asthmatic patients were treated with BDP (542 +/- 298 microg/day; 100-1200 microg/day) without any systemic administration of corticosteroids for at least 1 year. In premenopausal women, BMD as well as the biochemical markers of bone metabolism did not differ between control subjects and BDP-treated asthmatic patients. By contrast, in early postmenopausal women, BMD was significantly lower in BDP-treated asthmatic patients than in control subjects. In these early postmenopausal women, serum intact osteocalcin concentration was lower in the BDP-treated asthmatic patients than in the control subjects whereas urinary free pyridinoline (F-PYD) and free deoxypyridinoline (F-DPD) concentrations did not differ between the groups. Thus, early postmenopausal, but not premenopausal, asthmatic patients who were treated with inhaled BDP had reduced BMD, which was associated with a decreased level of the bone formation marker. Ovarian hormones may be protective against the adverse effect of inhaled BDP on bone metabolism in the premenopausal patients.
Fujita
K
K
University of Shiga Prefecture, Hikone, Japan.
Kasayama
S
S
Hashimoto
J
J
Nagasaka
Y
Y
Nakano
N
N
Morimoto
Y
Y
Barnes
P J
PJ
Miyatake
A
A
D015502:Absorptiometry, Photon; D000280:Administration, Inhalation; D000328:Adult; D000596:Amino Acids / Q000652:urine; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000139:chemically induced*; D004198:Disease Susceptibility; D005260:Female; D012739:Gonadal Steroid Hormones / Q000502:physiology; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000187:drug effects; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D017698:Postmenopause; D017697:Premenopause
D000596:Amino Acids; D018927:Anti-Asthmatic Agents; D015415:Biomarkers; D012739:Gonadal Steroid Hormones; D015675:Osteocalcin; C015484:pyridinoline; C036020:deoxypyridinoline; D001507:Beclomethasone